{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:47:44Z","timestamp":1762458464578,"version":"3.32.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,11,19]],"date-time":"2005-11-19T00:00:00Z","timestamp":1132358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00280-005-0138-9","type":"journal-article","created":{"date-parts":[[2005,11,18]],"date-time":"2005-11-18T13:09:18Z","timestamp":1132319358000},"page":"165-172","source":"Crossref","is-referenced-by-count":19,"title":["A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5\u00a0days every 3\u00a0weeks in patients with advanced solid tumors"],"prefix":"10.1007","volume":"58","author":[{"given":"Henry C.","family":"Pitot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff A.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Denis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McGovren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Langdon L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,19]]},"reference":[{"key":"138_CR1","first-page":"73","volume-title":"Advances in pharmacology","author":"Y Pommier","year":"1994","unstructured":"Pommier Y, Tanizawa A, Kohn KW (1994) Mechanisms of topoisomerase I inihibition by anticancer drugs. In: Liu LF (ed) Advances in pharmacology. Academic, New York, pp 73\u201392"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metestatic colorectal cancer: irinotecan study group. New Engl J Med 343:905\u2013914","journal-title":"New Engl J Med"},{"key":"138_CR3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.1999.17.2.685","volume":"17","author":"RL Drengler","year":"1999","unstructured":"Drengler RL, Kuhn JG, Schaaf LJ et al (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5\u00a0days every 3\u00a0weeks in patients with solid tumors. J Clin Oncol 17:685\u2013696","journal-title":"J Clin Oncol"},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"RM Simon","year":"1997","unstructured":"Simon RM, Friedlin B, Rubinstein LV et al (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89:1138\u20131147","journal-title":"J Natl Cancer Inst"},{"key":"138_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP et al (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (irinotecan) following intravenous infusion of [(14)C]irinotecan in cancer patients. Drug Metab Dispos 28:423\u2013433","journal-title":"Drug Metab Dispos"},{"key":"138_CR7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Non-compartmental analysis based on statistical moment therapy. In: Gibaldi M, Perrier D (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409\u2013417","edition":"2"},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"ML Rothenberg","year":"1993","unstructured":"Rothenberg ML, Kuhn JG, Burris HA et al (1993) Phase I and pharmacokinetic trial of weekly irinotecan. J Clin Oncol 11:2194\u20132204","journal-title":"J Clin Oncol"},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407\u20131412","journal-title":"Lancet"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fithc MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110\u2013115","journal-title":"J Clin Oncol"},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","volume":"38","author":"MM Borner","year":"2002","unstructured":"Borner MM, Schoffski P, de Wit R et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349\u2013358","journal-title":"Eur J Cancer"},{"key":"138_CR12","first-page":"427","volume":"54","author":"EK Rowinsky","year":"1994","unstructured":"Rowinsky EK, Grochow LB, Ettinger DS et al (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (irinotecan) administered as a ninety-minute infusion every three weeks. Cancer Res 54:427\u2013436","journal-title":"Cancer Res"},{"key":"138_CR13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D, Chabot GG, Armand JP et al (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3\u00a0weeks in cancer patients. J Clin Oncol 13:210\u2013221","journal-title":"J Clin Oncol"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","volume":"6","author":"GG Chabot","year":"1995","unstructured":"Chabot GG, Abigerges D, Catimel G et al (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (irinotecan) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141\u2013151","journal-title":"Ann Oncol"},{"key":"138_CR15","first-page":"3689","volume":"56","author":"LP Rivory","year":"1996","unstructured":"Rivory LP, Riou JF, Haaz M-CH et al (1996) Identification and properties of a major metabolite of irinotecan (irinotecan) isolated from the plasma of patients. Cancer Res 56:3689\u20133695","journal-title":"Cancer Res"},{"key":"138_CR16","first-page":"2236","volume":"6","author":"HC Pitot","year":"2000","unstructured":"Pitot HC, Goldberg RM, Reid JM et al (2000) Phase I dose finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236\u20132244","journal-title":"Clin Cancer Res"},{"key":"138_CR17","first-page":"3723","volume":"54","author":"E Gupta","year":"1994","unstructured":"Gupta E, Lestingi TM, Mick R et al (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723\u20133725","journal-title":"Cancer Res"},{"key":"138_CR18","first-page":"202a","volume":"16","author":"L Schaaf","year":"1997","unstructured":"Schaaf L, Ichhpurani N, Elfring G et al (1997) Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer (abstract). Proc Am Soc Clin Oncol 16:202a","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0138-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-005-0138-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0138-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T18:39:16Z","timestamp":1736102356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-005-0138-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,19]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1007\/s00280-005-0138-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2005,11,19]]}}}